Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice

British Journal of Pharmacology

Volumn 130, Issue 7, 2000, Pages 1646-1654

  Yamaguchi, Kouji ^a   Motegi, Katsutoshi ^a   Iwakura, Yoichiro ^b   Endo, Yasuo ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bisphosphonates; Histamine; Histidine decarboxylase; Interleukin 1; Lipopolysaccharide

Indexed keywords

ALENDRONIC ACID; AMINOBISPHOSPHONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; HISTIDINE DECARBOXYLASE; IBANDRONIC ACID; INCADRONIC ACID; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; GRAM NEGATIVE INFECTION; INFLAMMATION; KNOCKOUT GENE; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL;

EID: 0033862576     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703460     Document Type: Article

References (74)

1. ADAMI, S., BHALLA, A. K., DORIZZI, R., MONTESANI, F., ROSINI, S., SALVAGNO, G. & LO CASCIO, V. (1987). The acute phase response after bisphosphonate administration. Calcif. Tissue. Int., 41, 326-331.
2. ALHEIM, K., CHAI, Z., FANTUZZI, G., HASANVAN, H., MALINOWSKY, D., DI SANTO, E., GHEZZI, P. & DINARELLO, C.A. (1997). Hyperresponsive febrile reactions to interleukin(IL)-1α and IL-1β, and altered brain cytokine mRNA and serum cytokine levels, in IL-1β-deficient mice. Proc. Natl. Acad. Sci. U.S.A., 94, 2681-2686.
3. ALVARO-GRACIA, J.M,. ZVAIFLER, N.J., BROWN, C.B., KAUSHANSKY, K. & FIRESTEIN, G.S. (1991). Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocytes-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-α. J. Immunol., 146, 3365-3371.
4. AMIN, D., CORNELL, S.A., GUSTAFSON, S.K., NEEDLE, S.J., ULLRICH, J.W., BILDER, G.E & PERRONE, M.H. (1992). Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid Res., 33, 1657-1663.
5. AMIN, D., CORNELL, S.A., PERRONE, M.H. & BILDER, G.E. (1996). 1-Hydroxy-3-(methylpentylamino)-propylidenc-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Res., 46, 759-762.
6. ANDRÉ-SCHMUTZ, I., HINDELANG, C., BENOIST, C. & MATHIS, D. (1999). Cellular and molecular changes accompanying the progression from insulitis to diabetes. Eur. J. Immunol., 29, 245-255.
7. BAE, K-S., BAUMGARTNER, J.C., SHEARER, T.R. & DAVID, L.L. (1997). Occurrence of Prevotella nigrescens and Prevotella intermedia in infections of endodontic origin. J. Endodont., 23, 620-623.
8. BAUMGARTNER, J.C. & FALKLER, W.M. (1991). Bacteria in the apical 5 mm of infected root canals. J. Endodont., 17, 380-383.
9. BAZAN, J.F., TIMANS, J.C. & KASTELEIN, R.A. (1996). A new defined interleukin-1? Nature, 379, 591.
10. BENFORD, H.L., FRITH, J.C., AURIOLA, S., MÖNKKÖNEN, J. & ROGERS, M.J. (1999). Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol. Pharmacol., 56, 131-140.
11. BONJOUR, J.P., RIZZOLI, R., AMMANN, P. & CHEVALLEY, T. (1994). Bisphosphonates in clinical medicine. In Bone and Mineral Research, vol.8. ed. Heersche, N.M. & Kanis, J.K. pp 205-264. Amsterdam: Elsevier Science BV.
12. DAHLÉN, G. & MÖLLER, Å.J. R. (1992). Microbiology of endodontic infections. In: Contemporary Oral Microbiology and Immunology. ed. Slots, J. & Taubman, M.A. pp 444-475. St. Louis: Mosby Year Book.
13. DE, M., SANFORD, T.H. & WOOD, G.W. (1992). Detection of interleukin-1, interleukin-6, and tumor necrosis factor α in the uterus during the second half of pregnancy in the mouse. Endocrinol., 131, 14-20.
14. DINARELLO, C.A., NOVICK, D., PUREN, A.J., FANTUZZI, G., SHAPIRO, L., MÜHL, H., YOON, D.-Y., REZINIKOV, L.L., KIM, S.-H. & RUBINSTEIN, M. (1998). Overview of interleukin-18: more than an interferon-γ inducing factor. J. Leukocyte Biol., 63, 658-664.
15. DY, M., MACHAVOINE, F., LEBEL, B., ICHIKAWA, A., GASTINEL, L.N. & SCHNEIDER, E. (1993). Interleukin 3 promotes histamine synthesis in hematopoietic progenitors by increasing histidine decarboxylase mRNA expression. Biochem. Biophys. Res. Commun., 192, 167-173.
16. ENDO, Y. (1989). Induction of histidine and ornithine decarboxylase activities in mouse tissues by recombinant interleukin-1 and tumor necrosis factor. Biochem. Pharmacol., 38, 1287-1292.
17. ENDO, Y., KIKUCHI, T., NAKAMURA, M. & SHINODA, H. (1992a). Determination of histamine and polyamines in calcified tissues of mice: contribution of mast cells and histidine decarboxylase to the amount of histamine in the bone. Calcif. Tissue Int., 51, 67-71.
18. ENDO, Y., KIKUCHI, T., TAKEDA, Y., NITTA, Y., RIKIISHI, H. & KUMAGAI, K. (1992b). GM-CSF and G-CSF stimulate the synthesis of histamine and putrescine in the hematopoietic organs in vivo. Immunol. Lett., 33, 9-14.
19. ENDO, Y. & KUMAGAI, K. (1998). Induction by interleukin-1, tumor necrosis factor and lipopolysaccharide of histidine decarboxylase in the stomach and prolonged accumulation of gastric acid. Br. J. Pharmacol., 125, 842-848.
20. ENDO, Y., NAKAMURA, N., KIKUCHI, T., SHINODA, H., TAKEDA, K., NITTA, Y. & KUMAGAI, K. (1993). Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif. Tissue Int., 52, 248-254.
21. ENDO, Y., NAKAMURA, M,. NITTA, Y. & KUMAGAI, K. (1995). Effect of macrophage depletion on the induction of histidine decarboxylase by lipopolysaccharide, interleukin-1 and tumor necrosis factor. Br. J. Pharmacol., 114, 187-193.
22. ENDO, Y., SHIBAZAKI, M., NAKAMURA, M. & KOSUGI, H. (1999). Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br. J. Pharmacol., 126, 903-910.
23. ENDO, Y., SHIBAZAKI, M., NAKAMURA, M. & TAKADA, M. (1997). Contrasting effects of lipopolysaccharides (endotoxins) from oral black-pigmented bacteria and Enterobacteriaceae on platelets, a major source of serotonin, and on histamine-forming enzyme in mice. J. Infec. Dis., 175, 1404-1412.
24. ENDO, Y., SUZUKI, R. & KUMAGAI, K. (1986). Macrophages can produce factors capable of inducing histidine decarboxylase, a histamine-forming enzyme, in vivo in the liver, spleen, and lung of mice. Cell. Immunol., 97, 13-22.
25. ENDO, Y., TABATA, T., KURODA, H., TADANO, T., MATSUSHIMA, K. & WATANABE, M. (1998). Induction of histidine decarboxylase in skeletal muscle in mice by electrical stimulation, prolonged walking and interleukin-1. J. Physiol., 509, 587-598.
26. EVÉQUOZ, V., TRECHSEL, U. & FLEISCH, H. (1985). Effect of bisphosphonates on production of interleukin 1-like activity by macrophages and its effect on rabbit chondrocytes. Bone, 6, 439-444.
27. FANTUZZI, G., ZHENG, H., FAGGIONI, R., BENIGNI, F., GHEZZI, P., SIPE, J.D., SHAW, A.R. & DINARELLO, C.A. (1996). Effect of endotoxin in IL-1β-deficient mice. J. Immunol., 157, 291-296.
28. FISHER, J.E., ROGERS, M.J., HALASY, J.M., LUCKMAN, S.C., HUGHES, D.E., MASARACHIA, P.J., WESOLOWSKI, G., RUSSELL, R.G.G., RODAN, G.A. & RESZKA, A.A. (1999). Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclasts formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. U.S.A., 96, 133-138.
29. FLETSCH, H.A. (1997). Bisphosphonates: preclinical aspects and use in osteoporosis. Annal. Med., 29, 56-62.
30. FORMAN, B.M., RUAN, B., CHEN, J., SCHROEPFER, Jr, G.J. & EVANS, R.M. (1997). The orphan nuclear receptor LXRα is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Natl. Acad. Sci. U.S.A., 94, 10588-10593.
31. FUNAYAMA, H., MAYANAGI, H., TAKADA, H. & ENDO, Y. (2000). Elevation of histidine decarboxylase activity in the mandible of mice by Prevotella intermedia lipopolysaccharide and its augmentation by an aminobisphosphonate. Arch. Oral Biol., in press.
32. GALANOS, C., LÜDERITZ, O & WESTPHAL, O. (1969). A new method for the extraction of R lipopolysaccharides. Eur. J. Biochem., 9, 245-249.
33. GEDDES, A.D., D'SOUZA, S.M., EBENTINO, F.H. & KENNETH, J.L. (1994). Bisphosphonates: structure-activity relationships and therapeutic implicates. In Bone and Mineral Research/8. ed. Heersche, N.M. & Kanis, J.K. pp. 265-306. Amsterdam: Elsevier Science BV.
34. GIULIANI, N., PEDTAZZONI, M., PASSERI, G. & GIRASOLE, G. (1998). Bisphosphonates inhibits IL-6 production by human osteoblast-like cells. Scand. J. Rheumatol., 27, 38-41.
35. GLOMSET, J.A., GELB, M.H. & FARNSWORTH, C.C. (1992). Geranylgeranylated proteins. Biochem. Soc. Trans., 20, 479-484.
36. HARINCK, H.I.J., PAPAPOULOS, S.E., BLANKSMA, H.J., MOOLENAAR, A.J., WERMEIJ, P. & BIJVOET, O.L.M. (1987). Paget's disease of bone: early and late responses to three modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br. Med. J., 295, 1301-1305.
37. HORAI, R., ASANO, M., SUDO, K., KANUKA, H., SUZUKI, M., NISHIHARA, M., TAKAHASHI, M. & IWAKURA, Y. (1998). Production of mice deficient in genes for interleukin(IL)-1α, IL-1β, IL-1α/β, and IL-1 receptor antagonist shows that IL-1β is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med., 187, 1463-1475.
38. HURWITZ, A., PAYNE, D.W., PACKMAN, J.N., ANDREANI, C.L., RESNICK, C.E., HERNANDEZ, E.R. & ADASHI, E.Y. (1991). Cytokine-mediated regulation of ovarian function: interleukin-1 inhibits gonadotropin-induced androgen biosynthesis. Endocrinol., 129, 1250-1256.
39. KELLER, K. & FLIESLER, S.J. (1999). Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of isoprenoid pathway. Biochem. Biophys. Res. Commun., 266, 560-563.
40. KIKUCHI, H., WATANABE, M. & ENDO, Y. (1997). Induction by interleukin-1 (IL-1) of the mRNA of histidine decarboxylase, the histamine-forming enzyme, in the lung of mice in vivo and the effect of actinomycin D. Biochem. Pharmacol., 53, 1383-1388.
41. KOZAK, W., ZHENG, H., CONN, C.A., SOSZYNSKI, D., VAN DER PLOEG, L.H.T. & KLUGER, M.J. (1995). Thermal and behavioural effects of lipopolysaccharide and influenza in interleukin-1β-deficient mice. Am. J. Physiol., 269, R969-R977.
42. KUIDA, K., LIPPKE, J.A., KU, G., HARDING, M.W., LIVINGTON, D.J., SU, M.S.-S. & FLAVELL, R.A. (1995). Altered cytokine export and apoptosis in mice deficient in interleukin-1β converting enzyme. Science, 267, 2000-2003.
43. LEBEL, B., SCHNEIDER, E., PIQUET-PELLORCE, C., MACHAVOINE, F., KINDER, V., LUFFAU, G. & DY, M. (1990). Antigenic challenge of immunized mice induces endogenous production of IL-3 that increases histamine synthesis in hematopoietic organs. J. Immunol., 145, 1222-1226.
44. LI, P., ALLEN, H., BANERJEE, S., FRANKLIN, S., HERZOG, L., JOHNSTON, C., MCDOWELL, J., PASKIND, M., RODMAN, L., SALFELD, J., TOWNE, E., TRACEY, D., WARDWELL, S., WEI, F.-Y., WONG, W., KAMEN, R. & SESHARDRI, T. (1995). Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell, 80, 401-411.
45. MACAROL, V. & FRAUENFELDER, F.T. (1994). Pamidronate disodium and possible ocular adverse drug reactions. Am. J. Ophthamol., 118, 220-224.
46. MARTIN, M.B., ARNOLD, W., HEATH III, H.T., URBINA, J.A. & OLDFIELD, E. (1999). Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem. Biophys. Res. Commun., 263, 754-758.
47. MÖNKKÖNEN, J., KOPONEN, H.-M. & YLITALO, P. (1989). Comparison of the distribution of three bisphosphonates in mice. Pharmacol. Toxicol., 65, 294-298.
48. MÖNKKÖNEN, J., SIMILÄ, J. & ROGERS, M.J. (1998). Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sciences, 62, PL 95-PL 02.
49. NAIR, S.P., MEGHJI, S., WILSON, M., REDDI, K., WHITE, P. & HENDERSON, B. (1996). Bacterially induced bone resorption: mechanisms and misconceptions. Infect. Immun., 64, 2371-2380.
50. NAKAMUA, M., ANDO, T., MASATAKA, A., KUMAGAI, K. & ENDO, Y. (1996). Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br. J. Pharmacol., 119, 205-212.
51. NOACH, L.A., BOSMA, N.B., JANSEN, J., HOEK, F.J., VAN DEVENTER, S.J.H. & TYTGAT, G.N. (1994). Mucosal tumor necrosis factor-α, interleukin-1β, and interleukin-8 in patients with Helicobacter pylori infection. Scand. J. Gastroenterol., 29, 425-429.
52. OKAMURA, H., TSUTSUI, H., KOMATSU, T., YUTSUDO, M., HAKURA, A., TANIMOTO, T., TORIGOE, K., OKURA, T., NUKADA, Y., HATTORI, K., AKITA, K., NAMBA, M., TANABE, F., KONISHI, K., FUKUDA, S. & KURIMOTO, M. (1995). Cloning of a new cytokine that induces IFNγ production by T-cells. Nature, 378, 88-91.
53. OLKKONEN, N V.M. & STENMARK, H. (1997). Role of Rab GTPase in membrane traffic. Int. Rev. Cytol., 176, 1-85.
54. PENNANEN, N., LAPINJOKI, S., URTTI, A. & MÖNKKÖNEN, J. (1995). Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNFα secretion from RAW 264 cells in vitro. Pharmaceutical Res., 12, 916-922.
55. PIETSCHMANN, P., STOHLAWETZ, P., BROSCH, S., STEINER, G., SMOLEN, J.S. & PETERLIK, M. (1998). The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif. Tissue Int., 63, 325-330.
56. RAWLS, R. (1998). Dazzling phosphorus: international gathering of phosphorus chemists highlights medical applications, novel bonding of versatile element. Chem. Eng. News, 76, 38-40.
57. REITSCHEL, E.T., KIRIKAE, T., URICH, S., MAMAT, U., SCHMIDT, G., LOPPNOW, H., ULMER, A.J., ZÄHRINGER, U., SEYDEL, U., PADOVA, F.D., SCHREIER, M. & BRADE, H. (1994). Bacterial endotoxin: molecular relationships to structure, to activity and function. FASEB J., 8, 217-225.
58. RODAN, G.A. & FLEISCH, H.A. (1996). Bisphosphonates: mechanism of action. J. Clin. Invest., 97, 2692-2696.
59. SANDERS, J.L., TARJAN, G., FOSTER, S.A. & STERN, P.H. (1998). Alendronate/interleukin-1β cotreatment increases interleukin-6 in bone and UMR-106 cells: dose dependence and relationship to antiresorptive effect of alendronate. J. Bone Min. Res., 13, 786-792.
60. SANSONI, P., PASSERI, G., FAGNONI, F., MOHAGHEGHPOUR, N., SNELL, G., BRIANTI, V. & ENGLEMAN, E.G. (1995). Inhibition of antigen-presenting cell function by alendronate in vitro. J. Bone Min. Res., 10, 1719-1725.
61. SAUTY, A., PECHERSTORFER, M., ZIMMER-ROTH, I., FIORONI, P., JUILLERAT, L., MARKERT, M., LUDWIG, H., LEUENBERGER, P., BURCKHARDT, P. & THIÉBAUD, D. (1996). Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone, 18, 133-139.
62. SCHNEIDER, E., PIQUET-PELLORCE, C. & DY, M. (1990). New role for histamine in interleukin-3-induced proliferation of hematopoietic stem cells. J. Cell. Physiol., 143, 337-343.
63. SCHWEITZER, D.H., RUIT, M.O.V.D., PRUIJM, G.V.D., LÖWIK, C.W.G.M. & PAPAPOULOS, S.E. (1995). Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J. Bone Mineral Res., 10, 956-962.
64. SIRIS, E. (1993). Bisphosphonateas and iritis. Lancet, 2: 436-437.
65. SUGAWARA, S., SHIBAZAKI, M,. TAKADA, H., KOSUGI, K. & ENDO, Y. (1998). Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 ad tumour necrosis factor α in mice. Br. J. Pharmacol., 125, 735-740
66. TAKADA, H., HIRAI, H., FUJIWARA, T., KOGA, T., OGAWA, T. & HAMADA, H. (1990). Bacteriodes lipopolysaccharides (LPS) induce anaphylactoid and lethal reactions in LPS-responsive and -nonresponsive mice primed with muramyl dipeptide. J. Infect. Dis., 162, 428-434.
67. THIÉBAUD, D., SAUTY, A., BURCKHARDT, P., LEUENBERGER, P., SITZLER, L., GREEN, J.R., KANDRA, A., ZIESCHANGE, J. & IBARRA, DE PALACIOS, P. (1997). An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif. Tissue Int., 61, 386-392.
68. TORIGOE, K., USHIO, S., OKURA, T., KOBAYASHI, S., TANIAI, M,. KUNIKATA, T., MURAKAMI, T., SANOU, O., KOJIMA, H., FUJII, M., OHTA, T., IKEDA, M., IKEGAMI, H. & KURIMOTO, M. (1997). Purification and characterization of the human interleukin-18 receptor. J. Biol. Chem., 272, 25737-25742.
69. VAN BEEK, E., LÖWIK, C., VAN DER PLUIJM, G. & PAPAPOULOS, S. (1999a). The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonatyes. J. Bone Miner. Res., 14, 722-729.
70. VAN BEEK, E., PIETERMAN, E., COHEN, L., LÖWIK, C. & PAPAPOULOS, S. (1999b). Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res. Commun., 255, 491-494.
71. VAN BEEK, E., PIETERMAN, E., COHEN, L., LÖWIK, C. & PAPAPOULOS, S. (1999c). Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun., 264, 108-111.
72. WILSON, M. (1995). Biological activities of lipopolysaccharides from oral bacteria and their relevance to the pathogenesis of periodontitis. Sci. Prog., 78, 19-34.
73. YAMAGUCHI, K., MOTEGI, K., KURIMOTO, M. & ENDO, Y. (2000). Induction of the activity of the histamine-forming enzyme, histidine decarboxylase, in mice by IL-18 and by IL-18 plus IL-12. Inflammation Res., in press.
74. ZAMBON, J.J., GROSSI, S., DUNFORD, R., HARASZTHY, V.I., PREUS, H. & GENCO, R.J. (1994). Epidemiology of subgingival bacterial pathogens in periodontal disease. In: Molecular Pathogenesis of Periodontal Disease. ed. Genco, R.J., Hamada, S., Lehner, T., McGhee, J. & Mergenhagen, S. pp 3-12. Washington DC: ASM Press.